CSIMarket Company Name, Ticker, Competitors, else..
 
Purple Biotech Ltd  (NASDAQ: PPBT)
 

Purple Biotech Ltd's Suppliers Performance

PPBT's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
PPBT Costs vs Sales of Suppliers Growth

• More on PPBT Suppliers






Purple Biotech Ltd's Comment on Supply Chain


The company relies on third-party contract vendors to manufacture and supply active pharmaceutical ingredients (APIs) and other materials for its oncology therapeutic candidates, including IM1240, IM1305, CM24, and NT219. It does not manufacture any APIs internally. These third-party manufacturers are expected to comply with International Conference of Harmonization Q7 guidance and other regulatory requirements to provide quality materials in the necessary quantities and on schedule. Although multiple potential API manufacturers and suppliers exist, the company has not conducted extensive audits of their quality or availability. Changing or qualifying new suppliers involves significant costs and time, with risks of supply interruptions and challenges in maintaining consistent quality. The company anticipates continued reliance on third-party manufacturers even after potential marketing approval of its therapeutic candidates. To date, manufacturing by third parties has been conducted in relatively small quantities.

Purple Biotech Ltd's Comment on Supply Chain


The company relies on third-party contract vendors to manufacture and supply active pharmaceutical ingredients (APIs) and other materials for its oncology therapeutic candidates, including IM1240, IM1305, CM24, and NT219. It does not manufacture any APIs internally. These third-party manufacturers are expected to comply with International Conference of Harmonization Q7 guidance and other regulatory requirements to provide quality materials in the necessary quantities and on schedule. Although multiple potential API manufacturers and suppliers exist, the company has not conducted extensive audits of their quality or availability. Changing or qualifying new suppliers involves significant costs and time, with risks of supply interruptions and challenges in maintaining consistent quality. The company anticipates continued reliance on third-party manufacturers even after potential marketing approval of its therapeutic candidates. To date, manufacturing by third parties has been conducted in relatively small quantities.







PPBT's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Purple Biotech Ltd 0.71 0.04 -26.49 4
SUBTOTAL 0.00 0.00 0.00 -


Sources: Purple Biotech Ltd's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Purple Biotech Ltd’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.